Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
USP: mapping shows upstream concentration of APIs/KSMs; calls for benchmarks and advanced manufacturing support
Summary
United States Pharmacopeia told the House subcommittee its medicine‑supply mapping shows geographic concentration of key starting materials and APIs, and recommended a data‑driven approach that includes resiliency benchmarks, expanded supply‑chain visibility and support for advanced manufacturing technologies.
The United States Pharmacopeia (USP) told the House Energy and Commerce Subcommittee that its medicine supply map now covers roughly 94% of U.S. drug products and ingredients and shows a high degree of geographic concentration for key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
USP CEO Ronald J. Piervincenzi testified that the map identifies more than 100 vulnerable medicines that are both at high risk for disruption and hard to substitute…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
